Mintz advised the syndicate of underwriters on the deal. Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
This content is for Standard 1 Year members only. LoginJoin Now